SEC Form 4 · accession 0001213900-18-006696
DelMar Pharmaceuticals, Inc. · DMPI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Saiid Zarrabian
Officer — President and CEO · Director
Period of report
May 21, 2018
Accepted (ET)
May 22, 2018 · 6:25 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001498382
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $0.9825 | May 21, 2018 | A | 836,465 | A | — | May 21, 2028 | Common Stock | 836,465 | 836,465 | D |
Explanation of responses
- F11/6th of the options vest on November 21, 2018 with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on December 21, 2018.